JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

Search

Actinium Pharmaceuticals Inc

Abierto

1.69 19.86

Resumen

Variación precio

24h

Actual

Mínimo

1.3900000000000001

Máximo

1.69

Métricas clave

By Trading Economics

Ingresos

9.1M

-6.9M

Margen de beneficios

-821.235

Empleados

27

EBITDA

9.1M

-7.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+212.5% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-4.4M

47M

Apertura anterior

-18.17

Cierre anterior

1.69

Actinium Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

23 oct 2025, 23:51 UTC

Charlas de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct 2025, 23:37 UTC

Charlas de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct 2025, 22:58 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

23 oct 2025, 22:57 UTC

Charlas de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -2-

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct 2025, 22:17 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct 2025, 21:41 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct 2025, 21:05 UTC

Ganancias

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 oct 2025, 20:35 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct 2025, 20:28 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct 2025, 20:15 UTC

Charlas de Mercado
Ganancias

Global Commodities Roundup: Market Talk

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Adj EPS $1.71

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Sales $5.52B

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q EPS $1.67

23 oct 2025, 20:09 UTC

Ganancias

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct 2025, 20:07 UTC

Ganancias

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct 2025, 20:05 UTC

Ganancias

Intel 3Q Gross Margin 38.2% >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct 2025, 20:04 UTC

Ganancias

Intel: 4Q Guidance Excludes Altera >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Sees 4Q Adj EPS 8c >INTC

Comparación entre iguales

Cambio de precio

Actinium Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

212.5% repunte

Estimación a 12 Meses

Media 4.5 USD  212.5%

Máximo 5 USD

Mínimo 4 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Actinium Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
help-icon Live chat